HIMS Equity Alert: Kessler Topaz Meltzer & Check, LLP Alerts Shareholders of Securities Fraud Class Action Lawsuit Filed against Hims & Hers Health, Inc. (HIMS)

Associated Press

20-07-2025

Radnor, Pennsylvania--(Newsfile Corp. - July 19, 2025) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ('Hims & Hers') (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is August 25, 2025.
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Hims & Hers losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/hims-hers-health-inc?utm_source=NewsFile&utm_medium=PR
You can also contact attorney Jonathan Naji, Esq. by calling [phone] or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;" (2) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
[ This video cannot be displayed. Please visit the source: https://www.youtube.com/v/xuStgUOFgE8 ]
Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/xuStgUOFgE8
THE LEAD PLAINTIFF PROCESS:
Hims & Hers investors may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Hims & Hers investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/hims-hers-health-inc?utm_source=NewsFile&utm_medium=PR
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
[phone]
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259360